Deucravacitinib for Lupus

Recruiting in Palo Alto (17 mi)

+2 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: Bristol-Myers Squibb

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132

Research Team

Bristol-Myers Squibb

Principal Investigator

Bristol-Myers Squibb

Eligibility Criteria

This trial is for individuals with Systemic Lupus Erythematosus (SLE) or Discoid/Subacute Cutaneous Lupus Erythematosus (DLE/SCLE), who have already completed study IM011074 or IM011132. Specific eligibility criteria are not provided, but typically include a detailed medical history and current health status.

Inclusion Criteria

Participants must have completed Study IM011074 or Study IM011132 through the protocol-required treatment period

Participants must have received IP within 60 days of enrollment. Exceptions may be granted based upon consultation with BMS.

My doctor thinks deucravacitinib will likely help me.

Exclusion Criteria

Participants must not have any disease or medical condition that, in the opinion of the physician, would make the subject unsuitable for this protocol, would interfere with the interpretation of subject safety or considered unsuitable by the physician for any other reason

Other protocol-defined Inclusion/Exclusion criteria apply.

I do not have active Tuberculosis.

Treatment Details

Interventions

Deucravacitinib (Monoclonal Antibodies)

Trial OverviewThe trial is testing the continued use of Deucravacitinib, a medication potentially beneficial for lupus patients. It's designed for those who've previously been part of related studies and aims to assess long-term effects.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Administration of BMS-986165Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Bristol-Myers Squibb

Lead Sponsor

Trials

2,731

Recruited

4,127,000+

Headquarters

New York City, USA

Known For

Oncology & Cardiovascular

Top Products

Eliquis, Opdivo, Revlimid, Orencia

Christopher Boerner

Bristol-Myers Squibb

Chief Executive Officer since 2023

PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis